405 related articles for article (PubMed ID: 21483004)
21. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Berthold DR; Pond GR; Soban F; de Wit R; Eisenberger M; Tannock IF
J Clin Oncol; 2008 Jan; 26(2):242-5. PubMed ID: 18182665
[TBL] [Abstract][Full Text] [Related]
23. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K; De Bono JS; Flechon A; Heidenreich A; Voog E; Davis NB; Qi M; Bandekar R; Vermeulen JT; Cornfeld M; Hudes GR
Eur J Cancer; 2012 Jan; 48(1):85-93. PubMed ID: 22129890
[TBL] [Abstract][Full Text] [Related]
24. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
[TBL] [Abstract][Full Text] [Related]
25. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Sonpavde G; Matveev V; Burke JM; Caton JR; Fleming MT; Hutson TE; Galsky MD; Berry WR; Karlov P; Holmlund JT; Wood BA; Brookes M; Leopold L
Ann Oncol; 2012 Jul; 23(7):1803-8. PubMed ID: 22112969
[TBL] [Abstract][Full Text] [Related]
27. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
[TBL] [Abstract][Full Text] [Related]
28. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
29. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
30. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
[TBL] [Abstract][Full Text] [Related]
31. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
Zhou T; Zeng SX; Ye DW; Wei Q; Zhang X; Huang YR; Ye ZQ; Yang Y; Zhang W; Tian Y; Zhou FJ; Jie J; Chen SP; Sun Y; Xie LP; Yao X; Na YQ; Sun YH
PLoS One; 2015; 10(1):e0117002. PubMed ID: 25625938
[TBL] [Abstract][Full Text] [Related]
33. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
Sternberg CN; Whelan P; Hetherington J; Paluchowska B; Slee PH; Vekemans K; Van Erps P; Theodore C; Koriakine O; Oliver T; Lebwohl D; Debois M; Zurlo A; Collette L;
Oncology; 2005; 68(1):2-9. PubMed ID: 15741753
[TBL] [Abstract][Full Text] [Related]
34. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
35. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
36. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
38. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Hussain M; Rathkopf D; Liu G; Armstrong A; Kelly WK; Ferrari A; Hainsworth J; Joshi A; Hozak RR; Yang L; Schwartz JD; Higano CS
Eur J Cancer; 2015 Sep; 51(13):1714-24. PubMed ID: 26082390
[TBL] [Abstract][Full Text] [Related]
39. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Rugo HS; Stopeck AT; Joy AA; Chan S; Verma S; Lluch A; Liau KF; Kim S; Bycott P; Rosbrook B; Bair AH; Soulieres D
J Clin Oncol; 2011 Jun; 29(18):2459-65. PubMed ID: 21555686
[TBL] [Abstract][Full Text] [Related]
40. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]